You built the base camp. Fifty-plus markets consolidated. Veeva operations industrialized. Massive cost arbitrage delivered. The first climb is complete. Leadership celebrated the win, and rightfully so—the Global Capability Center (GCC) model has proven its value across the pharmaceutical industry.
Today, India has emerged as the global hub for life sciences GCCs, with 23 of the world's top 50 life sciences companies establishing centers in the country—a majority in just the past five years. These 80+ healthcare and life science GCCs employ over 250,000 professionals, handling 50% of commercial operations, 60% of regulatory affairs, and 45% of drug discovery functions for their global parent organizations. This is not a peripheral experiment—it is the backbone of modern pharma operations.
But while you were perfecting the base camp, the summit moved.
The GCC Mandate Has Moved from Efficiency to Innovation Faster Than Most Centers Have Transformed
The executive conversation has fundamentally shifted. The industry faces a $236 billion "patent cliff" between 2025 and 2030, with 190 drugs losing protection including 69 blockbusters generating over $1 billion annually. In this environment, what leadership wants is not more efficiency—it is strategic innovation powered by intelligent automation that can defend commercial performance in the face of biosimilar and generic competition.
The new summit demands capabilities that didn't exist in the original GCC mandate:
- Agentic AI for Commercial: Autonomous HCP engagement suggestion engines that adapt to physician behavior in real-time, powered by call activity and claims data
- Predictive Analytics: Prescriber churn models, next-best-action engines for field teams, and patient therapy initiation forecasting
- Omnichannel Orchestration: Dynamic journey personalization across rep visits, MSL interactions, speaker programs, digital channels, and patient support programs
This is not incremental improvement. This is a categorical transformation in the GCC's role within the enterprise—from a cost-efficient execution engine to the nerve center of commercial intelligence. AI and ML adoption in healthcare GCCs has surged from 65% to 86% over five years, yet many GCCs struggle to translate this technology investment into commercial impact.
The gap between ambition and capability has never been wider.
Operational Systems Built for Efficiency Have Become Barriers to the Innovation Mandate
Here is the paradox: the operational systems you built to survive at base camp are now the very things preventing you from reaching the summit. The factory processes that delivered efficiency—rigid SOPs, manual exception handling, ticket-based workflows—are now operational debt.
Consider the weight your GCC is still carrying:
Veeva CRM Data Migration Complexity
Veeva officially ended its reliance on Salesforce by September 2025, forcing pharmaceutical companies to migrate to Vault CRM or alternative platforms by 2030. Your GCC must now manage the migration of years of call data, MLR approvals, consent records, and account hierarchies across 50+ markets—while maintaining business continuity. Teams spend months reconciling legacy customizations instead of building predictive HCP engagement models.
Incentive Compensation's Manual Overhead
Your IC operations process 3,000+ territory exceptions and adjustment requests per quarter. Despite investments in modern IC management platforms, complex brand-specific rules, matrix reporting structures, and mid-quarter realignments still require manual calculation validation. A single error can freeze a $5M payout and erode field trust. Strategic analysts are trapped validating spreadsheets rather than designing AI-powered quota optimization.
AI Pilots Failing at Scale
You launched an AI-powered next-best-action pilot for your specialty sales force. It worked brilliantly in three markets. Then it hit the reality of commercial operations debt: inconsistent HCP specialty classifications across Veeva instances, non-standard affiliation hierarchies that don't map to claims data, and legacy territory definitions locked in undocumented business rules. The pilot stalls. Leadership questions ROI. The innovation agenda loses momentum—joining the 42% of pharma AI initiatives that fail to meet expectations.
This is not a technology problem. This is an operational architecture problem. And it is industry-wide: while pharma commercial services in GCCs have scaled 2.5x in the past five years, the transformation has been focused on volume, not velocity. Despite healthcare GCCs now representing 43% of their workforce dedicated to R&D and healthcare functions, the commercial operations layer remains trapped in factory-era workflows.
The pattern is clear: technology readiness is not the bottleneck. Operational readiness is. Major pharma investments—Sanofi's $437M expansion to 2,600 people by 2026, Bristol-Myers Squibb's $100M global innovation hub—are all betting on the GCC's ability to evolve from execution to innovation. But capital alone doesn't change operating systems.
GCCs Built for Capacity Must Now Build Contextual Capability to Own Enterprise AI
The GCC was originally designed to manage capacity—to process more tickets, faster, at lower cost. Success was measured in throughput metrics: ticket closure rates, SLA adherence, cost-per-FTE. These are the KPIs of a factory.
But the innovation summit demands a fundamentally different operating model. It requires capability—the ability to generate strategic insight, drive adoption, and manage rapid experimentation. The shift is profound:
| Base Camp Metrics (Capacity) | Summit Metrics (Capability) |
|---|---|
| Ticket Closure Rate | Field Adoption Rate |
| Zero Errors in Data Processing | Fast Experimentation Velocity |
| SLA Adherence | Time-to-Insight |
| Compliance with Process | Commercial Context Applied |
| Cost-per-FTE | Value-per-Innovation |
This is not a critique of the base camp model—it was exactly what was needed for the first climb. But you cannot reach the innovation summit while optimizing for factory metrics. The oxygen is different at altitude. The skillset is different. The entire operating rhythm must change.
The challenge is acute in life sciences. While India produces 2 million STEM graduates annually and has 2.7 million life sciences professionals, finding talent with both commercial pharma domain expertise and AI/ML product skills is extraordinarily difficult. The domain-heavy nature of pharma commercial functions—understanding HCP engagement dynamics, payer dynamics, patient journey nuances—makes this talent gap even wider. Meanwhile, GCCs are investing aggressively in AI without the operational foundation: platforms are deployed, data scientists are hired, but the underlying commercial processes remain manual and exception-heavy.
Transformation Requires Systematic Load-Shedding, Not a Leap to the Innovation Summit
You don't jump to the summit. You graduate to it. This requires a systematic load-shedding intervention—not a wholesale abandonment of your GCC's operational foundation, but a strategic offloading of the heavy gear that weighs down transformation.
The transformation pathway has three distinct stages:
Stage 1: Manage Your "Run" Operations with Surgical Precision
The base camp must remain operational. Rosters must be maintained. Data change requests must be processed. Tickets must be closed. But these "run" operations should not consume your strategic talent. They should be handled by specialized operational partners who convert tribal knowledge into codified digital logic, industrialize exception handling, and manage SLA-driven workflows.
This is the Strategic Sherpa model: a dedicated operational team manages the base camp so your high-value talent is free to climb. This is not outsourcing in the traditional sense—it is a deliberate architectural decision to separate execution from innovation.
Stage 2: Upskill from "Process" to "Product"
With operational weight removed, your GCC talent can shift from process execution to product ownership. Instead of processing territory alignment tickets, they design intelligent territory optimization algorithms. Instead of managing data change queues, they build self-service data governance platforms. Instead of generating standard reports, they create predictive analytics products that field teams trust and adopt.
This transition requires intentional capability development. According to recent industry data, 71% of GCCs now have active reskilling initiatives, a recognition that yesterday's skillset will not unlock tomorrow's mandate. Through our 5Cs framework, this stage demands investments in Context (commercial acumen) and Craft (product thinking), not just technical training.
Stage 3: Own Enterprise AI Strategy
At the summit, the GCC is no longer a back office—it is the nerve center of commercial intelligence. AI outputs are trusted by field leaders without manual overrides. Next-best-action recommendations drive real HCP engagement decisions. Omnichannel journeys dynamically adapt based on real-time behavioral signals. The GCC doesn't just support the commercial organization—it leads it.
But you only reach this summit if you are light enough to climb.
Top-Tier Mandates Will Accrue to Innovation-Ready GCCs as Transactional Work Is Commoditized
The window for this transformation is narrowing. India's overall GCC market is projected to grow from $64.6 billion to $99-105 billion by 2030—a massive expansion across technology, banking, and life sciences. Within this landscape, healthcare and pharma GCCs represent one of the fastest-growing segments, but growth will accrue disproportionately to centers that demonstrate innovation capability, not just operational scale. As pharma companies shift to hybrid operating models, they are increasingly internalizing high-value activities like market intelligence and pricing strategy while outsourcing transactional work.
The strategic implication is stark: pharma GCCs must climb to the innovation summit or risk being redefined as transactional outsourcing partners. Those that succeed will become "HQ twins"—co-owning global commercial strategy, driving AI-powered field effectiveness, and managing enterprise omnichannel orchestration. Those that remain trapped at base camp will find their mandate commoditized, their talent poached by higher-value innovation centers, and their strategic relevance eroded.
The base camp you built was essential. But it was never the destination. The real summit—where your GCC becomes a source of competitive advantage, not just operational efficiency—requires a fundamentally different way of climbing.
The question is not whether your team is capable of making the climb. The question is: What heavy gear are you still carrying that prevents you from starting?
Is your GCC trapped at base camp by operational debt?
Contact MoatRx to assess your operational load and design a systematic transformation pathway from efficiency to innovation.
